Anupam Rasayan Nov-24

Company Information

• Company name: Anupam Rasayan India Ltd.
• Address: 10th Floor, Icon Rio, Dumas Road, Surat, Gujarat, India - 395 007
• Contact information is provided, including phone numbers, email and website
• Script code: 543275
• Company incorporated: CIN-L24231GJ2003PLC042988

Investor Presentation

• Anupam Rasayan India Ltd. is providing an Investor Presentation
• The presentation covers Unaudited Financial Results
• The presentation covers the quarter and half year ended September 30, 2024
• The presentation is also available on the company website (www.anupamrasayan.com)
• This presentation follows Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 30

Financial Highlights (Q2FY25)

• Consolidated Total Revenue: ₹2,959 Mn, 14% growth compared to Q1
• Standalone Total Revenue: ₹1,945 Mn, 15% growth compared to Q1
• Consolidated EBITDA (Incl. Other Revenue): ₹824 Mn, 28% margin
• Standalone EBITDA (Incl. Other Revenue): ₹560 Mn, 29% margin
• Consolidated PAT: ₹306 Mn
• Standalone PAT: ₹140 Mn
• Capex Incurred: ₹6,012 Mn out of ₹6,700 Mn announced

New Products

• 2 new products were added in Q2FY25, bringing the total product count to 73

Managing Director's Message

• Q2FY25 saw a good recovery in the Agro segment after a previous demand slump
• The Pharma and Polymer segments have shown strong growth, fueled by 17 new molecules in FY24 and 3 additional molecules in H1FY25
• The planned launch of 3+ new molecules should accelerate growth
• Consolidated operating revenue for Q2FY25 grew 14% with a stable EBITDA margin of 28%
• Anticipated normalization of revenue with increasing volumes in the latter half of the year.
• Optimism about strong growth in the medium term

Consolidated Profit & Loss Summary (H1FY25 and H1FY24) Detailed Data

• Provides detailed financial data for the first half of financial years 2024 and 2023/2024 (H1FY24 and H1FY25) including revenue, expenses, gross profit, EBITDA, finance cost, taxation data
• Financial data provided for all the financial periods (Standalone and Consolidated)

Quarterly Financial Highlights (Q2FY24 and Q2FY24) Detailed Data

• Provides detailed financial data for the second quarter of 2025 ('Q2FY25') and 2024 ('Q2FY24') financial periods, including relevant details

Standalone Profit & Loss Summary (H1FY25 and H1FY24) Detailed Data

• Detailed financial data for the first half of FY25 and FY24 (H1FY25 and H1FY24)
• Includes revenue from operations, expenses, gross profit, and other financial data

Standalone Profit & Loss Summary (Q2FY25 and Q2FY24) Detailed Data

• Detailed financial data for the second quarter of FY25 and FY24 (Q2FY25 and Q2FY24)

Business Overview

• Specializes in multi-step synthesis
• Undertakes complex chemical reactions
• Serves globally relevant enterprises, including 31 MNCs, with cumulative 75 clients

Innovating Sustainable & Custom Solutions for Global Markets

• Established custom synthesis player with a 40-year track record.
• Has manufacturing capacity of ~27,200 MT. Spread over 6 facilities
• Strong technical capabilities in complex chemistries. Supported by 88 professionals in R&D .
• 73 complex products manufactured as of Q2FY25, spanning life sciences, specialty chemicals and other related areas
• 1,705+ committed employees. A strong management team

Evolution of Anupam

• Company history and milestones, including partnerships, product launches, and infrastructure expansion
• Milestones highlighted and their significance
• Expansions planned in various areas.

Chemical Conduits and Global Partnerships

• Summary of different business verticals of the company including Life Science Related, Other Specialty Chemicals; Key areas and specifics of the products
• List of major global clients such as Syngenta, SUMITOMO, ADAMA, DuPont. Nissei etc
• Contributes 90% (as of H1FY25) of its revenues

Charting New Frontiers with R&D Excellence

• Process technologies deployed, including examples of flow chemistry, photochemistry, etc.
• Strengths related to R&D & its significance to the company's growth
• Details of new chemical additions, such as Balz-Schiemann to Hofmann rearrangement reaction, reactions involved,
• Strengths and competencies in various key areas of specialty chemistries such as Aminolysis, Bromination, Chlorination, Condensations, Etherification, Diazotization, and Hydrolysis

Experienced Leadership & Deep Technical Talent Pool

• Details of senior executives and their relevant experience

Global Presence

• Presence in key markets like the US, Europe, and Japan
• Highlights specific business development personnel experience in given regions

Growth Drivers

• Growth of Polymer and Pharma Product Portfolio
• Execution of Signed LOIs and Contracts
• Expansion in Fluorination Chemistry
• Significant progress in Pharmaceuticals and Polymers

Growth of Pharma and Polymer Portfolio

• New strategic custom development products under pipeline
• Import substitute 'Key Starting Materials'
• Key intermediates to create new products under development

Pharmaceuticals

• Large, fast-growing market
• More than 10 molecules commercialized
• More than 30 molecules under pilot/R&D
• Significant progress made in Pharma

Polymer and Electronic chemicals

• Providing global clients with a range of high-value polymer and electronic chemical product
• Has significant strides made in this area , catering to global markets
• Backward integration to secure key raw materials
• Targeting ~$10B addressable market
• 35+ polymer and electronic chemical molecules at different stage of development in R&D and pilot stages

Strong Order Book – Recent LOI/Contracts Signed

• Summary of various significant contracts awarded in the recent past, including values in ₹ (Crores)
• LOIs signed and associated details like Tenor (Years), Segment, Customers, Status, Contract details

Anupam's Strategic Expansion in Fluorination with Tanfac

• Expansion plan with Tanfac for fluorinated product line
• Key benefits from the merger/acquisition, including the secure source of key raw materials

Expansion in Fluorination Chemistry

• Molecules of the fluorinated products and markets these are targeting
• Focused market segments addressed and customer types
• Revenue expectation potential for the expansion is estimated

Summary- Strengths and Key Highlights

• Manufacturing prowess, highlighting capacity expansion
• Strengths of R&D with a recognized R&D centre and capabilities in expanding product line
• Strong supply chain
• A sustainable business model with an established partner strategy for expansion (with MNCs and others)
• A multi-pronged strategy for long term growth

Corporate Office

• Headquarters address and contact information